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4-Alkylated Silver–N-Heterocyclic
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Cytotoxic Effects in Leukemia Cells
Silver lining: A new class of Ag–NHC
complex involving imidazoles with alkyl
side chains on the backbone 4-position
were realized by de novo synthesis
using new methods developed by our
research group. Two Ag–NHC com-
plexes were prepared with different side
chains, namely NHC-1 (methyl) and
NHC-2 (heptyl). Both complexes exhibit
potent cytotoxicity against two human
leukemia cell lines (HL60 and MOLM-13)
in the micromolar range.
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4-Alkylated Silver–N-Heterocyclic Carbene (NHC)
Complexes with Cytotoxic Effects in Leukemia Cells
Alexander H. Sandtorv,[a] Calum Leitch,[b] Siv Lise Bedringaas,[b] Bjørn Tore Gjertsen,[b, c] and
Hans-Renÿ Bjørsvik*[a]
Introduction
Numerous imidazoles are known for their potent biological ac-
tivities,[1] including analgesic,[2] antibacterial,[3] cytotoxic,[4] and
anticancer properties.[5] The imidazole framework is also an in-
tegral part of alkaloids,[6] and as a precursor for N-heterocyclic
carbene (NHC) ligands[7] in organometallic catalysis.[8] Metallic
silver has been known for centuries to possess bactericidal
properties and has been used as a treatment for gonorrhea[9]
before the development of modern antibiotics. In recent years,
silver has reemerged as a viable option in the treatment of in-
fectious diseases,[10] and silver-based products are currently
used as topical antibacterial agents.[11] One such example is
silver sulfadiazine,[12, 13] which has been associated with delayed
wound-healing.[14]
Silver–NHC complexes[15, 16] have been found to possess both
antibiotic[17] and anticancer properties[18] and have an untap-
ped potential as drug candidates. Furthermore, studies have
shown that synergistic effects that involve both the silver and
the NHC ligand play a profound role in the cytotoxicity of such
complexes.[19]
Theoretical calculations performed at our laboratories re-
vealed that substitution on the imidazole backbone is benefi-
cial for ligand-to-metal donation.[20] We envisioned that imida-
zoles elaborated with aliphatic groups on the backbone would
have a less labile CˇAg bond and thus be able to afford slow
release of silver, an effect that we believe could be beneficial
for a potential metallodrug. Although a great number of imida-
zole-based silver complexes have been reported, only few bear
backbone substitution such as bis-methylation,[21a] bis-chlorina-
tion,[21b] and alkenylation[21c] (Figure 1). However, the synthesis
and biological activity of imidazoles elaborated with aliphatic
alkyl chains on the backbone have not been previously report-
ed. To date, such substitution patterns have been difficult to
approach, due to lack of synthetic methodology. In fact, Ag–
NHC complexes have been realized by elaboration of imida-
zoles with embedded functionality,[21] or classical condensation
reactions from linear precursors.[22] A major drawback to these
strategies is low synthetic flexibility and inferior structural di-
versity achieved in the target imidazoles.
To address these challenges, we have devised and devel-
oped new synthetic methods for the preparation of 4-alkylated
imidazole–silver complexes. Along with this work, we have re-
vealed new synthetic methods for imidazole functionalization
that include selective halogenation,[23] Suzuki cross-coupling,[24]
Computational chemistry has shown that backbone-alkylated
imidazoles ought to be efficient ligands for transition metal
catalysts with improved carbene-to-metal donation. In this
work, such alkylated imidazoles were synthesized and com-
plexed with silver(I) by means of an eight/nine-step synthetic
pathway we devised to access a new class of biologically
active silver complexes. The synthesis involves selective iodina-
tion of the imidazole backbone, followed by Sonogashira cou-
pling to replace the backbone iodine. The installed alkyne
moiety is then subjected to reductive hydrogenation with
Pearlman’s catalyst. The imidazole N1 atom is arylated by the
palladium-catalyzed Buchwald N-arylation method. The imida-
zole N3 position was then methylated with methyl iodine,
whereupon the synthesis was terminated by complexation of
the imidazolium salt with silver(I) oxide. The synthetic pathway
provided an overall yield of ⇡20 %. The resulting complexes
were tested in vitro against HL60 and MOLM-13 leukemic cells,
two human-derived cell lines that model acute myeloid leuke-
mia. The most active compounds exhibiting low IC50 values of
14 and 27 mm, against HL60 and MOLM-13 cells, respectively.
The imidazole side chain was found to be essential for high cy-
totoxicity, as the imidazole complex bearing a C7 side chain at
the 4-position was four- to sixfold more potent than the corre-
sponding imidazole elaborated with a methyl group.
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Stille coupling,[25] and a method for Sonogashira coupling,[26]
the latter of which was used in the study described herein.
Results and Discussion
Chemistry
A retrosynthetic analysis to our target Ag–NHC is outlined in
Scheme 1. We envisioned that the target (TM) could be pro-
duced by complexation of imidazolium salt A with a suitable
silver salt. Two regioselective N-substitution reactions from 4-
(5)-alkylated-1H-imidazole B might lead to the desired salt A.
The backbone-substituted imidazole C could be produced
from the iodoimidazole E and an appropriate alkyne D through
a Sonogashira coupling reaction. The key intermediate E could
be produced from commercially available imidazole F.
To directly compare the effect on the activity of the com-
plexes with increasing length of the side chains, we devised
two different target molecules, NHC-1 (Scheme 2) and NHC-2
(Scheme 3), which differ by one feature, namely the substitu-
ent at the imidazole backbone position 4; NHC-1 contains
a methyl group, and NHC-2 contains a heptyl group. The two
NHC–silver complexes of this study can be prepared via two
different pathways. Because 4-methylimidazole 1 is commer-
cially available, a short pathway leading to NHC-1 was estab-
lished, a synthesis that comprises a) N-arylation,[27] b) N-methyl-
ation,[28] and c) complexation with silver[29] to obtain the NHC-
1 silver complex. The overall sequence provides a yield of
30 %, which corresponds to a mean step yield of 67 %.
The devised synthesis leading to NHC-2 (Scheme 3) com-
menced with the preparation of N-toluenesulfonyl-4-iodoimi-
dazole 4, which served as a key intermediate for the synthesis
of backbone-alkylated imidazoles. The synthetic pathway 1!4
involves a di-iodination step (a) followed by selective de-iodi-
nation (b), or a selective mono-iodination step (a’). The 4-iodi-
nated imidazole is then subjected to the introduction of an
auxiliary group at the N-tosylation step (c).[30] With the key sub-
strate 4 in hand, we used our recently disclosed method for
Sonogashira coupling[26] to perform the desired CˇC coupling
reaction of step (d). Reduction of the alkyne bond of 10 was
performed in excellent yield (92 %) by means of Pearlman’s cat-
alyst (Pd(OH)2/C) in methanol under a hydrogen atmosphere.
The following step, removal of the toluenesulfonyl auxiliary
group, was performed by treatment with concentrated hydro-
chloric acid in methanol at reflux in excellent yield (98 %). The
liberated imidazole derivative 12 was N-arylated [step (g)] by
using bromobenzene in toluene with Pd2(dba)3 and
Me4tBuXPhos as ligand
[27] in good yield (78 %). The last organic
reaction step of the synthetic pathway involved conversion of
the imidazole derivative into an imidazolium salt[28] 14 from
the N-aryl-4-subsituted imidazole derivative 13 by reacting
with methyl iodide at reflux in THF to obtain the N1-phenyl-
N3-methyl-4-methylimidazolium iodine salt 14 (57 %). Finally,
the target silver salts were prepared by using silver(I) oxide in
dichloromethane.[29] The nine-step synthesis providing NHC-2
afforded an overall yield of 19 %, which corresponds to a mean
step yield of 81 %.
Biology
The cytotoxic potential of metallodrugs may be influenced by
their capacity to release metals from the associated auxiliary
ligand. We hypothesized that the varied nature of the R group
of the 4-substituted imidazoles may further impact the cyto-
toxic potential of the compounds. To compare the biological
Scheme 1. Retrosynthetic analysis leading to 4-substituted imidazolium
silver complexes TM.
Scheme 2. Synthesis of N-1-phenyl-N-3-methyl-4-methylimidazol-2-yliden
silver iodide NHC-1. Reagents and conditions : a) PhBr (2), Pd2(dba)3,
Me4tBuXPhos, K2HPO4, toluene, 120 8C, 5 h, 87 %; b) MeI, THF, reflux, 4 h,
62 %; c) Ag2O, CH2Cl2, RT, 3 h, 56 %.
Figure 1. Previously disclosed biological active organosilver complexes.
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activity of the compounds, we incubated NHC-1 and NHC-2
with the human acute myeloid leukemia cell lines HL60 and
MOLM-13. Following 24 h incubation, the WST1 viability assay
was performed, revealing the estimated IC50 values of the com-
pounds to vary as a function of both the side chain R group
and the cell type used (Figure 2).
The p53-null cell line, HL60,
proved more sensitive to both
compounds. NHC-1 showed an
IC50 value of 78 mm in HL60 cells,
compared with an IC50 value of
123 mm in MOLM-13 cells. A simi-
lar trend was observed for the
more potent NHC-2 (HL60 IC50:
14 mm ; MOLM-13 IC50: 27 mm). To
confirm the compounds are truly
cytotoxic and not only antiproli-
ferative, we performed nuclear
staining with Hoechst 33342 in
both cell lines after 24 h incuba-
tion (NHC-1 at 100 mm, NHC-2 at
30 mm). Condensed and frag-
mented nuclei were observed in
both cell lines and are character-
istic of apoptosis (Figure 2).
Using the WST1 assay to com-
pare cell viability at 4, 12, and
24 h, we discovered the com-
pounds (NHC-1 at 100 mm and
NHC-2 at 20 mm) to induce rapid
cell death. For both cell lines
and complexes the majority of
cell death was observed after 4
or 12 h (Figure 3). The rapidity of
death was best exemplified in
the HL60 cell line. Finally, we
performed flow cytometry com-
bined with Annexin V staining in
HL60 cells treated with NHC-1,
NHC-2, or the chemotherapeutic
pyrimidine analogue cytarabine
(arabinofuranosyl cytidine) for
comparison. Cell viability was
determined by forward and side
scatter properties (Figure 4). Ex-
posure of the lipid membrane
component phosphatidylserine
(PS) allows its staining with An-
nexin V; this is indicative of
apoptosis. Furthermore, PS expo-
sure aids to effectively eliminate
large numbers of dying cells
from the systemic circulation
without releasing noxious intra-
cellular material.[31] Significant PS
staining was observed exclusive-
ly in HL60 cells treated with
NHC-1 and NHC-2, but was absent in cytarabine-treated cells.
Our experiments confirm the cytotoxic potential of the silver–
imidazole complexes and suggest that cell death in HL60 cells
is mechanistically distinct from that which occurs in cells treat-
ed with the chemotherapeutic cytarabine.
Figure 2. NHC-1 and NHC-2 are cytotoxic in leukemia cell lines. a) HL60 and b) MOLM-13 cells were treated with
NHC-1 and NHC-2 for 24 h, and cell viability was determined by WST1 assay to generate dose–response curves.
Experiments were performed in three independent replicates, and data are the mean⌃SD. c) HL60 and MOLM-13
cells were treated with NHC-1 (100 mm) and NHC-2 (30 mm) as indicated for 24 h, and nuclear morphology was de-
termined by Hoechst 33342 staining to identify dead cells.
Scheme 3. Synthesis of N-1-phenyl-N-3-methyl-4-heptylimidazol-2-yliden silver iodide NHC-2. Reagents and condi-
tions : a’) DIH, H2SO4 (cat.), H2O, 0 8C, 81 %; a) I2, KI, NaOH, RT, 24 h, b) Pd(OAc)2 (0.15 %), XPhos, K2HPO4, MeOH,
H2O, reflux, 90 min, (quant.) ; c) TosCl, NEt3, THF, RT, 24 h, 68 %; d) Pd(PPh3)4, CuI, NEt3, DMF, MW, 80 8C, 30 min,
79 %; e) H2 (1 atm), Pd(OH)2/C, MeOH, RT, 24 h, 92 %; f) HCl, MeOH, reflux, 2 h, 98 %; g) PhBr (2), Pd2(dba)3,
Me4tBuXPhos, K2HPO4, toluene, 120 8C, 5 h, 78 %; h) MeI, THF, reflux, 4 h, 57 %; i) Ag2O, CH2Cl2, RT, 3 h, 90 %.
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Conclusions
A novel class of Ag–NHC complexes encompassing imidazoles
furnished with alkyl side chains on the backbone 4-position
have been realized by de novo synthesis using new methods
developed in our research group. Two Ag–NHC complexes
were prepared with different side chains: NHC-1 (methyl) and
NHC-2 (heptyl). Both complexes were found to be potently cy-
totoxic against two human leukemia cell lines, HL60 and
MOLM-13, in the micromolar range. IC50 values for NHC-2 were
14 and 27 mm, respectively, and are motivation for further de-
velopment as an anticancer therapy. As the demand for novel
alternative cancer therapeutics remains unmet, metallodrugs
are an increasingly important compound class for investiga-
tion. The unique anti-leukemic properties of the Ag–NHC com-
plexes described herein further underscore the value of explor-




GC analyses were performed on a capillary gas chromatograph
equipped with a fused silica column (l : 25 m, i.d. : 0.20 mm, film
thickness: 0.33 mm) at a helium pressure of 200 kPa, split less/split
injector and flame ionization detector. DART-MS spectra were ob-
tained using PEG as an internal standard under positive ionization
mode with a ToF mass analyzer. 1H and 13C NMR spectra were re-
corded on instruments operating at 400 and 150 MHz, respectively.
Chemical shifts were referenced to the deuterated solvent used in
that experiment. All melting points are uncorrected. Synthesis of
precursors 2, 3, 4, and 10 were reported previously. The micro-
wave-assisted experiments were performed with a Biotage Initiator
Sixty EXP Microwave System oper-
ating at 0–400 W at 2.45 GHz. The
instrument operates in the temper-
ature range 40–250 8C, a pressure
interval of 0–20 bar (2 MPa,
290 psi) with reactor vial volumes
of 0.2–20 mL. Multiple attempts to
grow crystals of NHC-1 and NHC-2
suitable for X-ray analysis were
performed in various solvent sys-
tems, but unfortunately only amor-
phous material was obtained in
most cases.
N-Toluenesulfonyl-4-heptylimida-
zole 11. Imidazole (0.10 g) and
Pd(OH)2/C (15 % w/w) were trans-
ferred to a round-bottom flask
(50 mL) equipped with a magnetic
stir bar. MeOH (25 mL) was added,
and the flask was evacuated under
reduced pressure and flushed with
H2 from a balloon three times. The
reaction mixture was stirred vigo-
rously at room temperature for
24 h. The post-reaction mixture
was filtered through a pad of
Celite that was subsequently
washed with multiple small por-
tions of MeOH. The solvent was
evaporated to give the product as a tan oil in 92 % yield (purity:
 95 % as determined by GC) without need for further purification.
1H NMR (CDCl3): d= 7.91 (s, 1 H), 7.79 (d, 2 H, J = 8.0 Hz), 7.34 (d,
2 H, J = 7.0 Hz), 2.48 (t, 2 H, J = 7.4 Hz), 1.57 (2 H, m), 1.23 (8 H, m),
0.86 ppm (t, 3 H, J = 7.1 Hz); 13C NMR (CDCl3): d= 146.1, 136.3,
135.4, 130.5, 127.4, 112.9, 31.9, 29.3, 29.1, 28.7, 28.3, 22.7, 21.8,
14.2 ppm; HRMS (DART): m/z [M + H]+ calcd for C17H25N2O2S:
321.16367, found: 321.16367.
Figure 3. NHC-1 and NHC-2 induce rapid cell death in leukemia cell lines.
a) HL60 cells (TP53-null, FLT3 wild-type) were treated with NHC-1 (100 mm)
and NHC-2 (20 mm) for 4, 12, and 24 h, and viability was determined by
WST1 cell viability assay. b) MOLM-13 cells (TP53 wild-type, FLT3-internal
tandem mutation) were treated with NHC-1 (100 mm) and NHC-2 (20 mm) for
4, 12, and 24 h, and viability was determined by WST1 cell viability assay. Ex-
periments were performed in three independent replicates, and data are the
mean⌃SD.
Figure 4. NHC-1 and NHC-2 induce expression of cell-surface phosphatidylserine (PS) in HL60 cells. Cells were
treated with NHC-1 (100 mm), NHC-2 (20 mm), or cytarabine (5 mm) for 24 h. Cell viability was determined by com-
paring the forward scatter and side scatter properties with those of untreated control cells using flow cytometry,
as illustrated by figures in the upper row. Gated events represent viable cells. PS expression was determined by
Annexin V staining and analysis by flow cytometry as illustrated by histograms in the lower row. Events to the
right of the dashed lines are considered positive for Annexin V as determined by comparison with unstained con-
trol cells. All analyzed cells are taken from events deemed viable.
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4-(5)-Heptyl-1H-imidazole 12. Imidazole (2.94 mmol, 0.20 g) was
dissolved in MeOH (20 mL) in a round-bottom flask (25 mL). HCl
(concd, 1 mL) was added to this mixture in one portion. The reac-
tion mixture was held at reflux for 2 h, whereupon the MeOH was
evaporated and HCl (3 m, 10 mL) was added. The resulting mixture
was extracted with Et2O (2 î 20 mL), and the organic phases dis-
carded. The aqueous phase was made alkaline with NaOH (4 m)
and again extracted with Et2O (3 î 20 mL). The organic extracts
were combined, dried over anhydrous Na2SO4, filtered, and concen-
trated under reduced pressure to provide the product at high
purity. The product was isolated as a tan oil in 98 % yield. 1H NMR
(CDCl3): d= 11.07 (1 H, m, br), 7.64 (1 H, s), 6.76 (1 H, s), 2.59 (t, 2 H),
1.61 (m, 2 H), 1.26 (m, 8 H), 0.85 ppm (t, 3 H); 13C NMR (CDCl3): d=
137.0, 134.2, 117.7, 31.9, 29.4, 29.4, 29.2, 26.6, 22.8, 14.2 ppm;
HRMS (DART): m/z [M + H]+ calcd for C10H19N2 : 167.15482, found:
167.15466.
General procedure for Pd-catalyzed N-arylation coupling reac-
tion between 4-(5)-alkyl-1H-imidazoles and bromobenzene.[27] To
an oven-dried tube was transferred imidazole (1.2 mmol), K3PO4
(424 mg, 2.0 mmol), and bromobenzene (2.0 mmol). The vial was
sealed with a septum and carefully flushed with argon through the
septum. A second oven-dried tube was charged with Pd2(dba)3
(0.0125 mmol) and Me4tBuXPhos (0.025 mmol) before it was sealed
with a septum and flushed with argon. The catalyst was dissolved
in a mixture of anhydrous toluene (0.83 mL) and anhydrous 1,4-di-
oxane (0.17 mL), and the resulting dark-purple mixture was stirred
at 120 8C for 3 min, at which point the color of the mixture turned
to red–brown. The catalyst was then transferred to the first vial,
and the reaction mixture was heated at 120 8C for 5 h. At the end
of the reaction time, the mixture was cooled to room temperature,
diluted with EtOAc (10 mL), washed with brine (2 mL), and dried
over MgSO4. The drying agent was filtered off, and the organic sol-
vent was removed under reduced pressure. The crude product was
then purified by flash chromatography with the eluent systems
specified below.
N-Phenyl-4-methylimidazole 3. Isolated as a yellow oil by silica
gel column chromatography [EtOAc/hexanes (4:6)!(1:1)] in 87 %
yield. 1H NMR (CDCl3): d= 7.74 (1 H, s), 7.44 (2 H, t, J = 7.6 Hz), 7.33
(3 H, m), 6.99 (s, 1 H), 2.29 ppm (s, 3 H); 13C NMR (CDCl3): d= 139.6,
134.6, 134.7, 129.9, 127.1, 121.1, 114.7, 13.8 ppm.
N-Phenyl-4-heptylimidazole 13. The product was isolated by flash
silica gel chromatography [EtOAc/hexanes (1:9)!(1:1)] as pale crys-
tals in 78 % yield. Rf = 0.58 [EtOAc/hexanes (1:1)] ; mp: 53.9–55.0 8C;
1H NMR (CDCl3): d= 7.77 (s, 1 H), 7.45 (t, 2 H, J = 7.5 Hz), 7.33 (m,
3 H, J = 8.3 Hz), 7.00 (s, 1 H), 2.62 (t, 2 H, J = 7.8 Hz), 1.69 (t, 2 H, J =
7.4 Hz), 1.31 (m, 8 H), 0.87 ppm (t, 3 H, J = 7.4 Hz); 13C NMR (CDCl3):
d= 144.8, 137.7, 134.7, 129.9, 127.2, 121.3, 114.2, 320, 29.5, 29.5,
29.5, 29.3, 28.6, 22.8, 14.3 ppm; HRMS (DART): m/z [M + H]+ calcd
for C16H23N2 : 243.18558, found: 243.1860.
General procedure for N-3-methylation of N-1-phenyl-4-alkylimi-
dazole.[28] N-phenyl-4-alkylimidazole (2.0 mmol) was dissolved in
THF (15 mL). Methyl iodide (4.00 mmol) was added in one portion,
and the reaction mixture was held at reflux for 4 h. The post-reac-
tion mixture was allowed to cool, resulting in crystallization of the
product which was filtered, washed with small portions of hexane,
and air-dried to furnish the product.
N-1-Phenyl-N-3-methyl-4-methylimidazolium iodide. Isolated as
a white solid in 62 % yield. 1H NMR (CDCl3): d= 10.12 (s, 1 H), 7.65
(d, 2 H, J = 7.8 Hz), 7.60 (s, 1 H), 7.42 (m, 3 H), 3.98 (s, 3 H), 2.37 ppm
(s, 3 H); 13C NMR (CDCl3): d= 135.2, 134.5, 132.8, 130.7, 130.3, 122.0,
117.8, 34.9, 9.7 ppm; HRMS (ESI): m/z [M]+ calcd for C11H13N2 :
173.10787, found: 173.10779; [M2I]
+ calcd for C22H26N4I: 473.12021,
found: 473.12594.
N-1-Phenyl-N-3-methyl-4-heptylimidazolium iodide. Isolated as
a tan solid in 57 % yield. 1H NMR (CDCl3): d= 10.60 (s, 1 H), 7.74 (d,
2 H, J = 7.9 Hz), 7.54 (m, 3 H), 4.12 (s, 3 H), 2.69 (t, 2 H, J = 8.0 Hz),
1.71 (m, 3 H), 1.35 (m, 7 H), 0.87 ppm (t, 3 H, J = 6.9 Hz); 13C NMR
(CDCl3): d= 137.3, 135.9, 134.7, 130.8, 130.4, 122.1, 116.7, 34.9, 31.7,
29.3, 29.0, 27.3, 23.9, 22.8, 14.2 ppm; HRMS (DART): m/z [M + HˇI]+
calcd for C17H25N2 : 257.20177, found: 257.20179.
General procedure for the synthesis of imidazole-based silver
complexes.[29] Imidazolium salt (1.77 mmol) was dissolved in CH2Cl2
(15 mL), and silver(I) oxide (0.89 mmol) was added in one portion.
The black reaction mixture was stirred for 2 h 25 min, at which
point the mixture became pale brown. The solution was poured
into a beaker containing hexanes (100 mL), resulting in precipita-
tion of a crystalline solid. This was filtered and recrystallized from
CH2Cl2 to furnish the silver complexes.
N-1-Phenyl-N-3-methyl-4-methylimidazol-2-yliden silver(I)
iodide. Isolated as a white solid in 56 % yield after pooling three
crops. 1H NMR (CDCl3): d= 7.52 (m, 2 H), 7.39 (m, 3 H), 6.98 (s, 1 H),
3.82 (s, 3 H), 2.29 ppm (s, 3 H); 13C NMR (CDCl3): d= 140.4, 131.3,
129.8, 1286, 124.1, 119.0, 36.9, 10.0 ppm; HRMS (DART): m/z [M +
HˇAgI]+ calcd for C11H13N2: 173.10732, found: 173.10215.
N-1-Phenyl-N-3-methyl-4-heptylimidazol-2-yliden silver(I) iodide.
Isolated as a white solid in 90 % yield. 1H NMR (CDCl3): 7.54 (d, 2 H),
7.42 (m, 3 H), 6.95 (s, 1 H), 3.84 (s, 3 H), 2.58 (m, 2 H), 1.65 (m, 2 H),
1.30 (m, 8 H), 0.89 ppm (t, 3 H); 13C NMR (CDCl3): d= 182.6, 140.4,
136.0, 129.9, 128.7, 124.0, 118.1, 36.7, 31.8, 29.3, 29.1, 27.8, 24.5,
22.8, 14.2 ppm; HRMS (DART): m/z [MˇAgI]+ calcd for C17H25N2:
257.20177, found: 257.20156.
Biology
The human cell lines MOLM-13 and HL60 were purchased from
American Type Culture Collection (ATCC; Manassas, VA, USA) and
cultured in RPMI 1640 (Invitrogen), containing 10 % heat-inactivat-
ed fetal bovine serum (GE Healthcare, Life Sciences), 2 mm l-gluta-
mine, and 50 U mLˇ1 penicillin/streptomycin (Sigma–Aldrich). Evalu-
ation of viability/apoptosis was performed as described previous-
ly.[32, 33] Cell analysis after drug treatment (2 î 105 cells per mL) was
carried out by fixing cells in 8 % formaldehyde in PBS, DNA-specific
staining with Hoechst 33342 (Invitrogen; 10 mg mLˇ1), followed by
counting of normal and fragmented/condensed cell nuclei in an in-
verse fluorescence microscope (Zeiss Axio Vert.A1), or by flow cyto-
metric analysis and Annexin staining. Annexin staining (Invitrogen)
was performed in accordance with the manufacturer’s recom-
mended procedure and run on the Guava easyCyte flow Cytometer
(EMD Millipore). The WST1 assay cell proliferation reagent (Life Sci-
ences) was used in accordance with the manufacturer’s procedure,
followed by respective reading of luminescence and absorbance
(Spectra Max Gemini EM, Molecular Devices). All cell viability assays
were performed in flat-bottomed 96- or 24-well tissue culture test
plates.
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[3] M. Antolini, A. Bozzoli, C. Ghiron, G. Kennedy, T. Rossi, A. Ursini, Bioorg.
Med. Chem. Lett. 1999, 9, 1023.
[4] T. Lindel, P. R. Jensen, W. Fenical, B. H. Long, A. M. Casazza, J. Carboni,
C. R. Fairchild, J. Am. Chem. Soc. 1997, 119, 8744.
[5] M. J. Wanner, G. J. Koom, Chem. Soc. Perkin Trans. 1 2002, 1877.
[6] H. R. Bjørsvik, A. H. Sandtorv in Marine Sponges (Ed. : Atta-ur-Rahman),
Elsevier, Amsterdam, 2014, Vol. 42, Ch. 2, pp. 33.
[7] a) X. Hu, Y. Tang, P. Gantzel, K. Meyer, Organometallics 2003, 22, 612;
b) W. Chen, B. Wu, K. Matsumoto, J. Organomet. Chem. 2002, 654, 233;
c) Synthesis (Ed. : S. P. Nolan), Wiley-VCH, Weinheim, 2006 ; d) M. K. Sa-
mantaray, V. Katiyar, K. Pang, H. Nanavati, P. Ghosh, J. Organomet. Chem.
2007, 692, 1672; e) O. Kuhn, Functionalised N-Heterocyclic Carbene Com-
plexes, Wiley, 2010 ; f) O. K¸hl, Chem. Soc. Rev. 2007, 36, 592.
[8] F. Wang, L. J. Liu, W. Wang, S. Li, M. Shi, Coord. Chem. Rev. 2012, 256,
804.
[9] S. M. Mirsattari, R. R. Hammond, M. D. Sharpe, F. Y. Leung, G. B. Young,
Neurology 2004, 62, 1408.
[10] D. J. Barillo, D. E. Marx, Burns 2014, 40, S3 – S8.
[11] B. S. Atiyeh, M. Costagliola, S. N. Hayek, S. A. Dibo, Burns 2007, 33, 139.
[12] C. L. Fox in Modern Treatment, Hoeber Medical Division, Harper & Row,
New York, 1967.
[13] A. C. Miller, M. R. Rashid, L. Falzon, E. M. Elamin, S. Zehtabchi, J. Am.
Acad. Dermatol. 2012, 66, e159.
[14] C. A. R. Lee, H. Leem, J. Lee, K. C. Park, Biomaterials 2005, 26, 4670.
[15] A. Liu, X. Zhang, W. Chen, H. Qiu, Inorg. Chem. Commun. 2008, 11, 1128.
[16] a) J. C. Garrison, W. J. Youngs, Chem. Rev. 2005, 105, 3978; b) K. M. Hindi,
M. J. Panzer, C. A. Tessier, C. L. Cannon, W. J. Youngs, Chem. Rev. 2009,
109, 3859; c) S. Patil, A. Deally, B. Gleeson, H. M¸ller-Bunz, F. Paradisi, M.
Tacke, Appl. Organomet. Chem. 2010, 24, 781.
[17] a) A. Kascatan-Nebioglu, M. J. Panzner, C. A. Tessier, C. L. Cannon, W. J.
Youngs, Coord. Chem. Rev. 2007, 251, 884; b) S. Roland, C. Jolivalt, T.
Cresteil, L. Eloy, P. Bouhours, A. Hequet, V. Mansuy, C. Vanucci, J. M.
Paris, Chem. Eur. J. 2011, 17, 1442; c) W. Streciwilk, J. Cassidy, F. Hacken-
berg, H. M¸ller-Bunz, F. Paradisi, M. Tacke, J. Organomet. Chem. 2014,
749, 88.
[18] For selected examples of Ag(I)–imidazolium complexes with anticancer
properties, see: a) S. Ray, R. Mohan, J. K. Singh, M. K. Samantaray, M. M.
Shaikh, D. Panda, P. Ghosh, J. Am. Chem. Soc. 2007, 129, 15042; b) D. A.
Medvetz, K. M. Hindi, M. J. Panzner, A. J. Ditto, Y. H. Yun, W. J. Youngs,
Met.-Based Drugs 2008, 384010; c) M. L. Teyssot, A. S. Jarrousse, M.
Manin, A. Chevry, S. Roche, F. Norre, C. Beudoin, L. Morel, D. Boyer, R.
Mahiou, A. Gautier, Dalton Trans. 2009, 6894; d) C. H. Wang, W. C. Shih,
H. C. Chang, Y. Y. Kuo, W. C. Hung, T. G. Ong, W. S. Li, J. Med. Chem.
2011, 54, 5245; e) L. Eloy, A. S. Jaarousse, M. L. Teyssot, A. Gautier, L.
Morel, C. Jolivalt, T. Cresteil, S. Roland, ChemMedChem 2012, 7, 805;
f) W. Liu, R. Gust, Chem. Soc. Rev. 2013, 42, 755; For a recent review see:
g) S. Budagumpi, R. A. Haque, S. Endud, G. U. Rehman, A. W. Salman,
Eur. J. Inorg. Chem. 2013, 4367; h) C. N. Banti, S. K. Hadjikakou, Metallo-
mics 2013, 5, 569.
[19] a) D. C. F. Monteiro, R. M. Phillips, B. D. Crossley, J. Fielden, C. E. Willans,
Dalton Trans. 2012, 41, 3720; b) P. Padmaja, G. K. Rao, A. Indrasena,
B. V. S. Reddy, N. Patel, A. B. Shaik, N. Reddy, P. K. Dubey, M. P. Bhadra,
Org. Biomol. Chem. 2015, 13, 1404.
[20] G. Occhipinti, H. R. Bjørsvik, V. R. Jensen, J. Am. Chem. Soc. 2006, 128,
6952.
[21] a) P. de Frÿmont, N. M. Scott, E. D. Stevens, T. Ramnial, O. C. Lightbody,
C. L. B. Macdonald, J. A. C. Clyburne, C. D. Aberneth, S. P. Nolan, Organo-
metallics 2005, 24, 6301; b) S. Patil, J. Claffey, J. Deally, M. Hogan, B.
Gleeson, L. M. Menÿndez Mÿndez, H. M¸ller-Bunz, F. Paradisi, M. Tacke,
Eur. J. Inorg. Chem. 2010, 1020; c) K. M. Hindi, T. J. Siciliano, S. Durmus,
M. J. Panzner, D. A. Medvetz, D. V. Reddy, L. A. Hogue, C. E. Hovis, J. K.
Hilliard, R. J. Mallet, C. A. Tessier, C. L. Cannon, W. J. Youngs, J. Med.
Chem. 2008, 51, 1577; d) S. Patil, K. Dietrich, A. Deally, B. Gleeson, H.
M¸ller-Bunz, F. Paradisi, M. Tacke, Helv. Chim. Acta 2010, 93, 2347; e) S.
Patil, A. Deally, B. Gleeson, F. Hackenberg, H. M¸ller-Bunz, F. Paradisi, M.
Tacke, Z. Anorg. Allg. Chem. 2011, 637, 386; f) S. Patil, K. Dietrich, A.
Deally, F. Hackenberg, L. Kaps, H. M¸ller-Bunz, R. Schobert, M. Tacke,
Helv. Chim. Acta 2011, 94, 1551.
[22] W. Liu, K. Bensdorf, A. Hagenbach, U. Abram, B. Niu, A. Mariappan, R.
Gust, Eur. J. Med. Chem. 2011, 46, 5927.
[23] A. H. Sandtorv, H. R. Bjørsvik, Adv. Synth. Catal. 2013, 355, 499.
[24] A. H. Sandtorv, H. R. Bjørsvik, Adv. Synth. Catal. 2013, 355, 3231.
[25] A. H. Sandtorv, K. W. Tçrnroos, H. R. Bjørsvik, Eur. J. Org. Chem. 2015,
3506.
[26] A. H. Sandtorv, H. R. Bjørsvik, Eur. J. Org. Chem. 2015, DOI : 10.1002/
ejoc.201500520.
[27] S. Ueda, M. Su, S. L. Buchwald, J. Am. Chem. Soc. 2012, 134, 700.
[28] a) J. Berding, J. A. van Paridon, V. H. S. van Rixel, E. Bouwman, Eur. J.
Inorg. Chem. 2011, 2450; b) B. D. Stringer, L. M. Quan, P. J. Barnard,
D. J. D. Wilson, C. F. Hogan, Organometallics 2014, 33, 4860.
[29] H. M. J. Wang, I. J. B. Lin, Organometallics 1998, 17, 972.
[30] M. D. Cliff, S. G. Pyne, Tetrahedron 1996, 52, 13703.
[31] M. Miyanishi, K. Tada, M. Koike, Y. Uchiyama, T. Kitamura, S. Nagata,
Nature 2007, 450, 435 – 439.
[32] E. McCormack, I. Haaland, G. VenÂs, R. B. Forthun, S. Huseby, G. Gausdal,
S. Knappskog, D. R. Micklem, J. B. Lorens, Ø. Bruserud, B. T. Gjertsen,
Leukemia 2012, 26, 910.
[33] G. Gausdal, B. T. Gjertsen, E. McCormack, P. Van Damme, R. Hovland, C.
Krakstad, Ø. Bruserud, K. Gevaert, J. Vandekerckhove, S. O. Døskeland,
Blood 2008, 111, 2866.
Received: May 28, 2015
Published online on August 6, 2015
ChemMedChem 2015, 10, 1522 – 1527 www.chemmedchem.org ⌫ 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim1527
Full Papers
Supporting Information
4-Alkylated Silver–N-Heterocyclic Carbene (NHC)
Complexes with Cytotoxic Effects in Leukemia Cells
Alexander H. Sandtorv,[a] Calum Leitch,[b] Siv Lise Bedringaas,[b] Bjørn Tore Gjertsen,[b, c] and
Hans-Ren! Bjørsvik*[a]
cmdc_201500234_sm_miscellaneous_information.pdf
Page 1 of 41 
Table of ContentV 
Synthesis of additional derivatives. ................................................................................... 2!
1H-NMR of N-phenyl-4-methylimidazole (3) ................................................................... 3!
13C-NMR of N-phenyl-4-methylimidazole (3) .................................................................. 4!
COSY 2D-NMR spectrum of N-phenyl-4-methylimidazole (3) ....................................... 5!
1H-NMR spectrum of N-1-phenyl-N-3-methyl-4-methylimidazolium iodide (4) ............. 6!
13C-NMR spectrum of N-1-phenyl-N-3-methyl-4-methylimidazolium iodide (4) ............ 7!
HRMS spectrum of N-1-phenyl-N-3-methyl-4-methylimidazolium iodide (4) ................. 8!
2D-COSY NMR spectrum of N-1-phenyl-N-3-methyl-4-methylimidazolium iodide (4) . 9!
1H-NMR spectrum of NHC-1 .......................................................................................... 10!
13C-NMR spectrum of NHC-1 ......................................................................................... 11!
HRMS spectrum of NHC-1 ............................................................................................. 12!
1H-NMR spectrum of N-tosyl-4-heptylimidazole (11) .................................................... 13!
13C-NMR spectrum of N-tosyl-4-heptylimidazole (11) ................................................... 14!
HRMS spectrum of N-tosyl-4-heptylimidazole (11) ....................................................... 15!
1H-NMR spectrum of 4-(5)-heptyl-1H-imidazole (12) .................................................... 16!
13C-NMR spectrum of 4-(5)-heptyl-1H-imidazole (12) .................................................. 17!
HRMS spectrum of 4-(5)-heptyl-1H-imidazole (12) ....................................................... 18!
1H-NMR spectrum of N-phenyl-4-heptylimidazole (13) ................................................. 19!
13C-NMR spectrum of N-phenyl-4-heptylimidazole (13) ................................................ 20!
HRMS spectrum of N-phenyl-4-heptylimidazole (13) .................................................... 21!
COSY 2D-NMR spectrum of N-phenyl-4-heptylimidazole (13) ..................................... 22!
1H-NMR spectrum of N-1-phenyl-N-3-methyl-4-heptylimidazolium iodide (14) .......... 23!
13C-NMR spectrum of N-1-phenyl-N-3-methyl-4-heptylimidazolium iodide (14) ......... 24!
1H-NMR spectrum of NHC-2 .......................................................................................... 25!
13C-NMR spectrum of NHC-2 ......................................................................................... 26!
HRMS spectrum of NHC-2 ............................................................................................. 27!
2D COSY-NMR spectrum NHC-2 .................................................................................. 28!
1H-NMR spectrum of N-tosyl-4-(2-phenylethyl)imidazole (15) ..................................... 29!
13C-NMR spectrum of N-tosyl-4-(2-phenylethyl)imidazole (15) .................................... 30!
HRMS spectrum of N-tosyl-4-(2-phenylethyl)imidazole (15) ........................................ 31!
1H-NMR spectrum of 4-(5)-(2-phenylethyl)-1H-imidazole (16) ..................................... 32!
13C-NMR spectrum of 4-(5)-(2-phenylethyl)-1H-imidazole (16) .................................... 33!
HRMS spectrum of 4-(5)-(2-phenylethyl)-1H-imidazole (16) ........................................ 34!
1H-NMR spectrum of N-tosyl-4-decylimidazole (17) ..................................................... 35!
13C-NMR spectrum of N-tosyl-4-decylimidazole (17) .................................................... 36!
HRMS spectrum of N-tosyl-4-decylimidazole (17) ......................................................... 37!
COSY-NMR spectrum of N-tosyl-4-decylimidazole (17) ............................................... 38!
HRMS spectrum of 4-(5)-decyl-1H-imidazole (18) ........................................................ 41!
Page 2 of 41 
 
 
Synthesis of additional derivatives. 
 
N-tosyl-4-(2-phenylethyl)imidazole 15 [NEW]. Isolated as pale crystals 
in a yield of 98%. Rf = 0.58 [EtOAc: Hx (4:6)]. 1H-NMR (CDCl3): δ 7.94 
(s, 1H), 7.77 (d, 2H, J = 8.5 Hz), 7.34 (d, 2H, J = 8.3 Hz), 7.19 (m, 3H), 
7.11 (d, 2H, J = 7.5 Hz), 6.89 (s, 1H), 2.91 (m, 2H), 2.82 (m, 2H), 2.45 (s, 3H). 13C-NMR 
(CDCl3): δ 146.1, 144.8, 141.3, 136.3, 135.3, 130.5, 128.5, 128.4, 127.4, 126.1, 113.4, 35.0, 
30.2, 21.9. HRMS (DART): m/z [MH]+ calcd. for C18H19N2O2S: 327.11617, found 327.11499 
 
4-(5)-(2-phenylethyl)-1H-limidazole 16 [NEW]. Isolated in high purity 
(100%, based on GC) as a tan oil in a yield of 86 %. 1H-NMR (CDCl3): δ 
9.90 (1H, s, br), 7.55 (1H, s), 7.25 (2H, m), 7.14 (m, 3H), 6.76 (s, 1H), 2.93 
(s, 4H). 13C-NMR (CDCl3): δ 141.7, 136.7, 134.5, 128.7, 126.2, 117.7, 36.1, 29.2. HRMS 
(DART): m/z [MH]+ calcd. for C11H13N2: 173.10787, found: 173.10765. 
 
N-tosyl-4-decylimidazole 17 [NEW]. Isolated as tan crystals in the yield of 
98%. 1H-NMR (CDCl3): δ 7.91 (s, 1H), 7.80 (d, 2H, J = 8.5 Hz), 6.96 (s, 
1H), 2.49 (t, 2H, J = 7.7 Hz), 2.43 (s, 3H), 1.58 (m, 2H), 1.25 (m, 16H), 
0.87 (t, 3H, J = 7.0 Hz ).  13C-NMR (CDCl3): δ 146.1, 136.2, 135.4, 130.5, 
127.4, 127.4, 112.8, 32.0, 29.71, 29.66, 29.5, 29.44, 29.37, 28.7, 28.3, 22.8, 21.8, 14.3. 
HRMS (DART): m/z [MH]+ calcd. for C20H31N2O2S: 363.21062, found 363.21053. 
 
4-(5)-decyl-1H-limidazole 18 [NEW]. Isolated as a yellow oil that was prone 
to crystallization in a yield of 58%. 1H-NMR (CDCl3): δ 9.00 (1H, br, s), 7.00 
(1H, s), 3.63 (2H, s, br), 1.49 (1H, m), 1.67 (2H, m), 1.26 (15H, m), 0.86 (3H, 
t).13C-NMR (CDCl3): δ 134.4, 133.1, 114.5, 31.9, 29.57, 29.53, 29.3, 29.2, 
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13C-NMR of N-phenyl-4-methylimidazole (3) 
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13C-NMR spectrum of N-1-phenyl-N-3-methyl-4-methylimidazolium iodide (4) 
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HRMS spectrum of N-1-phenyl-N-3-methyl-4-methylimidazolium iodide (4) 
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2D-COSY NMR spectrum of N-1-phenyl-N-3-methyl-4-methylimidazolium iodide 
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1H-NMR spectrum of NHC-1  
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13C-NMR spectrum of NHC-1 
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HRMS spectrum of NHC-1 
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1H-NMR spectrum of N-tosyl-4-heptylimidazole (11) 
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13C-NMR spectrum of N-tosyl-4-heptylimidazole (11) 
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1H-NMR spectrum of 4-(5)-heptyl-1H-imidazole (12) 
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13C-NMR spectrum of 4-(5)-heptyl-1H-imidazole (12) 
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HRMS spectrum of 4-(5)-heptyl-1H-imidazole (12) 
 




1H-NMR spectrum of N-phenyl-4-heptylimidazole (13) 
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13C-NMR spectrum of N-phenyl-4-heptylimidazole (13) 
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COSY 2D-NMR spectrum of N-phenyl-4-heptylimidazole (13) 
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1H-NMR spectrum of N-1-phenyl-N-3-methyl-4-heptylimidazolium iodide (14) 
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13C-NMR spectrum of N-1-phenyl-N-3-methyl-4-heptylimidazolium iodide (14) 
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1H-NMR spectrum of NHC-2 
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13C-NMR spectrum of NHC-2 
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HRMS spectrum of NHC-2 
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2D COSY-NMR spectrum NHC-2 
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1H-NMR spectrum of N-tosyl-4-(2-phenylethyl)imidazole (15) 
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13C-NMR spectrum of N-tosyl-4-(2-phenylethyl)imidazole (15) 
 




HRMS spectrum of N-tosyl-4-(2-phenylethyl)imidazole (15) 
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1H-NMR spectrum of 4-(5)-(2-phenylethyl)-1H-imidazole (16) 
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13C-NMR spectrum of 4-(5)-(2-phenylethyl)-1H-imidazole (16)  
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HRMS spectrum of 4-(5)-(2-phenylethyl)-1H-imidazole (16) 
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1H-NMR spectrum of N-tosyl-4-decylimidazole (17) 
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1H-NMR spectrum of 4-(5)-decyl-1H-imidazole (18) 
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13C-NMR spectrum of 4-(5)-decyl-1H-imidazole (18) 
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HRMS spectrum of 4-(5)-decyl-1H-imidazole (18) 
 
 
 
